SpyGlass Pharma, Inc.
SGP
$26.20
$1.034.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 461.35% | 400.88% | 194.08% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 136.28% | 107.58% | 75.76% | ||
| Operating Income | -136.28% | -107.58% | -75.76% | ||
| Income Before Tax | -128.98% | -56.61% | -49.48% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -128.98% | -56.61% | -49.48% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -128.98% | -56.61% | -49.48% | ||
| EBIT | -136.28% | -107.58% | -75.76% | ||
| EBITDA | -136.00% | -106.75% | -75.39% | ||
| EPS Basic | 84.41% | 82.48% | -25.21% | ||
| Normalized Basic EPS | 84.40% | 82.48% | -25.21% | ||
| EPS Diluted | 84.41% | 82.48% | -24.63% | ||
| Normalized Diluted EPS | 84.40% | 82.48% | -25.21% | ||
| Average Basic Shares Outstanding | 1,368.25% | 793.78% | 19.38% | ||
| Average Diluted Shares Outstanding | 1,368.25% | 793.78% | 19.38% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||